Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?

Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for the management of RR-TB, South Africa announced that bedaquiline (BDQ) would be provided to virtually all RR-TB pat...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of tuberculosis and lung disease 2020-10, Vol.24 (10), p.1073-1080
Main Authors: Ndjeka, N., Hughes, J., Reuter, A., Conradie, F., Enwerem, M., Ferreira, H., Ismail, N., Kock, Y., Master, I., Meintjes, G., Padanilam, X., Romero, R., Schaaf, H. S., Riele, J. te, Maartens, G.
Format: Article
Language:English
Subjects:
Antitubercular Agents - therapeutic use
Bedaquiline
Cohort Studies
Drug Resistance
Humans
Injectable-Free Regimens
Linezolid
Shorter Treatment Regimen
South Africa - epidemiology
Tuberculosis, Multidrug-Resistant - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for the management of RR-TB, South Africa announced that bedaquiline (BDQ) would be provided to virtually all RR-TB patients on shorter or longer regimens. South Africa has been the global leader in accessing BDQ for patients with RR-TB, who now represent 60% of the global BDQ cohort. The use of BDQ within a shorter modified regimen has generated the programmatic data underpinning the most recent change in WHO guidelines endorsing a shorter, injectable-free regimen. Progressive policies on access to new drugs have resulted in improved favourable outcomes and a reduction in mortality among RR-TB patients in South Africa. This supported global policy change. The strategies underpinning these bold actions include close collaboration between the South African National TB Programme and partners, introduction of new TB diagnostic tools in closely monitored conditions and the use of locally generated programmatic evidence to inform country policy changes. In this paper, we summarise a decade´s work that led to the bold decision to use a modified, short, injectable-free regimen with BDQ and linezolid under carefully monitored programmatic conditions.
ISSN:1027-3719
1815-7920
DOI:10.5588/ijtld.20.0174